Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Copaiba aqueous mouthwash is an investigational botanical therapy derived from the oleoresin of *Copaifera* trees, which are native to the Amazon region. It is being developed for the management of oral mucositis, a common and debilitating side effect in patients with head and neck cancer undergoing radiotherapy or chemotherapy. The mouthwash is formulated to leverage the natural anti-inflammatory, antimicrobial, and wound-healing properties of copaiba. In a Phase I clinical trial conducted at the Instituto Nacional de Câncer (INCA) in Brazil, the solution demonstrated a favorable safety profile with no dose-limiting toxicities at concentrations up to 15%, used four times daily. The study suggests that it may serve as a safe alternative or adjunct to low-power laser therapy, particularly in tumor regions where laser use is contraindicated.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on copaiba aqueous mouthwash.